What is the Prognosis for Patients with TRK Fusion-Positive Cancers?
The prognosis for patients with TRK fusion-positive cancers has improved with the introduction of TRK inhibitors. Many patients experience significant tumor shrinkage and prolonged progression-free survival. However, the prognosis can vary depending on factors such as the type of cancer, the presence of additional genetic alterations, and the development of drug resistance. Continued research and clinical trials are essential to optimize treatment strategies and improve long-term outcomes for these patients.
